Categories AlphaGraphs, Earnings, Health Care

Earnings: Trxade Health (MEDS) reports 6% drop in Q3 revenue; loss narrows

Trxade Health Inc (NASDAQ: MEDS), a leading health service IT company, reported a modest decline in its third-quarter revenues. Meanwhile, the company’s net loss narrowed sharply from the prior-year period.

Trxade Q3 2022 earnings infographic

Third-quarter revenues declined 6% year-over-year to $2.40 million. Despite that, Trxade’s net loss narrowed to $0.50 million or $0.06 per share in the September quarter from $1.30 million or $0.16 per share in the comparable period of fiscal 2021.

“These first nine months of 2022 have been an exciting and challenging time for TRxADE. We continue to focus the Company’s strategic plans and partnerships working towards creating sustainable value for our stockholders. I am pleased with the growth we have experienced in our TRxADE platform. We continue to achieve key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities,” said Trxade’s CEO Suren Ajjarapu.


Check this space to read management/analysts’ comments on Trxade’s Q2 2022 results


Shares of Trxade traded slightly lower early Tuesday, after closing the previous session lower. In the past six months, the stock experienced volatility.

Prior Performance

  • Trxade Q2 2022 earnings infographic
  • Trxade Q1 2022 earnings infographic
  • Trxade Q4 2021 earnings infographic
  • Trxade Health Q3 2021 earnings

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top